TerminatedPhase 3ACTRN12608000304336

Dexmedetomidine Sedation for Awake Fibreoptic Bronchoscopy

Feasibility and Safety of Dexmedetomidine Sedation for Patients presenting for Awake Fibreoptic Bronchoscopy

Sponsor

Keat Lee

Enrollment

100 participants

Start Date

Dec 15, 2008

Study Type

Interventional

Conditions

Safety and Feasibility of Dexmedetomidine Sedation for Awake Fibreoptic Bronchoscopy

Summary

We aim to trial dexmedetomidine as a sedating agent for awake diagnostic fibreoptic bronchoscopy. It has a number of unique properties which we feel would be useful - sedating, reduces discomfort and stress during potentially uncomfortable procedures. We would be monitoring for any problems or adverse events during this trial.

Eligibility

Sex: Both males and femalesMin Age: 18 Yearss

Plain Language Summary

Simplified for easier understanding

This study tests whether a sedation drug called dexmedetomidine can safely and effectively keep patients comfortable during an awake fiber-optic bronchoscopy (a procedure where a thin camera is passed through the airway). It is for adults aged 18 or older who are scheduled for this procedure.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Dexmedetomidine sedation as an intravenous infusion to obtain sedation. Initial bolus of 0.5mcg/kg over 10 minutes followed by an infusion of 0.2-0.7mcg/kg/h, titrating to a Ramsay Sedation Score of 4 during the procedure. This infusion would be ceased once bronchoscopy is completed. The estimated time for the bronchoscopy would be about 15-20 minutes.

Locations(1)

Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12608000304336